尼达尼布治疗间质性肺疾病的作用机制研究进展

Research progress on mechanism of action of nintedanib in treatment of interstitial lung diseases

尼达尼布是德国勃林格殷格翰公司研发的一种酪氨酸激酶抑制剂,目前被获批用来治疗多种间质性肺病,本文主要对尼达尼布治疗间质性肺病的作用机制进行综述,包括特发性肺纤维化、系统性硬化症相关间质性肺病、进行性纤维化性间质性肺病以及类风湿性关节炎相关间质性肺病,总结出尼达尼布通过抑制多种促纤维化信号通路及干预多种炎症相关的表型,从而在持续性肺纤维化和炎症免疫相关间质性肺疾病中发挥治疗作用,以期为尼达尼布在间质性肺疾病的临床用药提供理论基础。

Nintedanib is a tyrosine kinase inhibitor developed by Boehringer Ingelheim,Germany.It is currently approved for the treatment of a variety of interstitial lung diseases.This article focuses on the effect of nintedanib in the treatment of interstitial lung diseases,and the related mechanisms are reviewed,including idiopathic pulmonary fibrosis,systemic sclerosis-related interstitial lung disease,progressive fibrotic interstitial lung disease,and rheumatoid arthritis-related interstitial lung disease.It inhibits a variety of pro-fibrotic signaling pathways and intervenes in a variety of inflammation-related phenotypes,playing a therapeutic role in persistent pulmonary fibrosis and inflammatory immune-related interstitial lung diseases.This review aims to provide a theoretical basis for the clinical use of nintedanib in interstitial lung diseases.